SEATTLE, Jan. 29, 2013 /PRNewswire-iReach/ -- Global BioClinical (GBC) is pleased to announce that it has been awarded a contract from the National Institutes of Health (NIH) / National Cancer Institute (NCI) to support the Cancer Genome Atlas (TCGA) project (http://cancergenome.nih.gov).
Global BioClinical (GBC) will establish and manage a research biospecimen collection network of cancer treatment centers that will enroll subjects diagnosed with various types of cancer and who are scheduled to undergo surgical treatment for their disease. Participating subjects will consent to donate biospecimens including a pre-surgical blood sample and resected surplus surgical tissues. Collected biospecimens and de-identified medical and pathological information will be delivered to TCGA affiliated biospecimen testing laboratories where they will undergo analysis. The collected biospecimens must meet a stringent set of criteria so that extracted DNA and RNA is suitable for advanced genomic analysis and sequencing technologies.
It is the overall goal of TCGA to examine a large number of biopspecimens - up to 500 samples for each tumor type - thus providing the statistical power needed to produce a comprehensive genomic profile of each cancer type and information essential to identifying the best targets for the development of new cancer treatment drugs. In addition, all TCGA research teams are analyzing the same samples. This results in a very complete, detailed and reliable view of cancer genomes. For TCGA cancer samples studied, both a sample of cancerous and normal tissue will be collected. This will also allow researchers to identify the genomic changes that may play a role in the development of cancer.
About Global BioClinical:
Global BioClinical (GBC) is a contract consulting and clinical research organization (CRO) with core expertise in organizational and project management, clinical trial planning and execution, and human biospecimens. GBC works with clients in the life sciences and healthcare research sector including early-stage and established medical device and biotechnology companies, pharmaceutical companies, medical centers and health systems, research and academic institutions, government agencies and sub-contractors, venture capital groups, and not-for-profit groups. GBC supports predictive, prognostic, personalized, and participatory medicine with the leading goal of moving healthcare products to the market more quickly, with less risk, and with a greater return on investment.
GBC – GLOBAL BIOCLINICAL
Expertise-Based Clinical Research Services
Consulting – Business – Trials – Biospecimens
93 S. Jackson St., Suite #80042
Seattle, WA 98104-2818 U.S.A.
Main: +1 888 659 1221
Linked In: www.linkedin.com/company/global-bioclinical
GBC Press Global BioClinical
GBC Press, GBC, 8886591221, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Global BioClinical